QSQuantSignals Research/Studies
Try FST free

← All studies

FAIL

Long-dated momentum options with a take-profit: do the anecdote's rules beat buying the same contracts every month?

Do 270-day at-the-money calls on the 12-month momentum leaders, held about two weeks with a +50% or +100% take-profit, make money after costs on 17 large US names from 2017 to June 2024, and do they beat buying the same contracts on every scored date? Do puts on the weakest names, or a rule that switches side with the market's 200-day trend, do better?

No. None of the four pre-registered rules passed. The primary call rule's mean return after costs was +0.2% in discovery (587 trades) and +3.8% in validation (157), but the discovery and validation lower bounds were -3.9% and -3.3%. The +100% take-profit version was +0.9% and +3.9% (587 and 157 trades), with lower bounds -3.6% and -3.3%. Puts on the weakest names lost 3.7% in discovery (434 trades) and 9.3% in validation (129). The switching rule was -0.1% (631) and +1.3% (162). Buying the same contracts on every scored date did about as well: the whole-window signal-minus-baseline difference was about zero (its lower bound between -6.5% and -7.2%), inside the 13.7% difference the sample could detect, so it does not separate the rules from the baseline. In the 3 x $1,500 simulation of the primary rule, 10x in 63 sessions happened on 0.00-0.01% of paths.

Backtested by QS Research

Pre-registration

Four trials fixed before any option quote was read for a result: calls on the top five 12-month momentum leaders, take-profit at +50% or +100%; the mirror with puts on the five weakest names; and a fourth rule that holds the call list when the market is above its 200-day average and the put list otherwise. Contracts are 0.50-delta, 270-day options bought at the ask, with a 10-session time stop; the judge is every scored name bought on the same contract with no momentum condition. The 17 names, decision dates, entry lists and data snapshot were pinned before the run. Discovery is 2017-2022 and validation is 2023 to June 2024; the holdout from July 2024 is sealed. The family is four trials, so each one-sided lower bound is read at 0.05/4. Three dated amendments (expiry listed at entry, the fourth switching trial, and the data pin) were made before any result.

Registered 2026-11-03

Amendments

A holdout sample is sealed: its results stay unread until the study is final.

Trials · 4 trials · 0 passed · judged at N = 4 trials; 2965 trials run in total

TrialVerdict
Trial 1 (primary): calls on the momentum leaders, take-profit 1.5xFAILcounted
Trial 2: calls on the momentum leaders, take-profit 2xFAILcounted
Trial 3: puts on the laggards, take-profit 1.5xFAILcounted
Trial 4: calls or puts by the market's 200-day trend, take-profit 1.5xFAILcounted
Trial 1 registration, charged before any quote was read (not a result)RESULTnot counted
Trial 2 registration, charged before any quote was read (not a result)RESULTnot counted
Trial 3 registration, charged before any quote was read (not a result)RESULTnot counted
Trial 4 registration, charged before any quote was read (not a result)RESULTnot counted

Limitations

The numbers: every trial's checks, metrics, curve and yearly results, and the provenance

2 published versions · current 13a2eac48c658f2d, published 2026-11-21

Put these signals to work

This page is free. Members get the live version of every QS Research signal. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans